News

Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

Feb 5, 2026 - 13:02
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer sales strategy.

Related Posts

Shares of Arm plunge in after hours trading amid concerns over smartphone chips

Shares of Arm plunge in after hours trading amid concer...

Feb 5, 2026

Jim Cramer says the software sell-off creates opportunities in stocks outside of tech

Jim Cramer says the software sell-off creates opportuni...

Feb 5, 2026

E.l.f. Beauty posts earnings beat, raises full-year guidance

E.l.f. Beauty posts earnings beat, raises full-year gui...

Feb 5, 2026

Amazon makes Alexa+ AI assistant available to everyone in the U.S. nearly a year after launch

Amazon makes Alexa+ AI assistant available to everyone ...

Feb 5, 2026

Amazon's push to make AI cheaper — and why it matters to reigniting the stock

Amazon's push to make AI cheaper — and why it matters t...

Feb 5, 2026

Alphabet resets the bar for AI infrastructure spending

Alphabet resets the bar for AI infrastructure spending

Feb 5, 2026